Skip to content

Prevalence of Musculoskeletal Disorders of Upper Limb in Type 1 Diabetes Patients

Prevalence of Musculoskeletal Disorders of Upper Limb in Type 1 Diabetes Patients

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05164562
Acronym
TMS-DT1
Enrollment
150
Registered
2021-12-20
Start date
2022-01-07
Completion date
2023-01-01
Last updated
2022-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 Diabetes

Keywords

musculoskeletal disorders, prevalence

Brief summary

Osteopenia and osteoporosis, particularly related to insulinopenia, are common in type 1 diabetes and increase the risk of fractures. Musculoskeletal disorders of the upper limb are a common complication of type 1 diabetes. However, there is no official recommendation for screening for musculoskeletal disorders in France.

Detailed description

The aim of the study is to describe prevalence of musculoskeletal disorders of upper limb in type 1 diabetes patients.

Interventions

OTHERData collection

Description: musculoskeletal disorders of upper limb evaluation

Sponsors

Université de Reims Champagne-Ardenne
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* male or female * aged of 18 and more * with type 1 diabetes * agreeing to participate in the study

Exclusion criteria

* none

Design outcomes

Primary

MeasureTime frameDescription
musculoskeletal disorders of upper limbDay 0musculoskeletal disorders of upper limb evaluated using Quick Dash (Quick Disabilities of Arm, Shoulder and Hand). Quick Dash is a 11 items questionnaire that measures an individual's ability to complete tasks, absorb forces, and severity of symptoms. The QuickDASH tool uses a 5-point Likert scale from which the patient can select an appropriate number corresponding to his/her severity/function level. The score ranges from 0 (no disability) to 100 (most severe disability), a higher score indicates a greater level of disability and severity, whereas, lower score indicates a lower level of disability.

Countries

France

Contacts

Primary ContactBrigitte DELEMER, MD
bdelemer@chu-reims.fr0326788101
Backup ContactCoralie BARBE, MD
currs@univ-reims.fr0326918822

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026